The trial will evaluate the safety, effectiveness and ability of the shot, dubbed mRNA-1403, to induce an immune response ...
[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 ...
The seeds of Spanish filmmaker Pedro Almodóvar’s later cinematic work are scattered throughout the pages of “The Last Dream,” ...
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...